Vertex Q4/FY23 revenue $2.52B/$9.87B; FY24 guidance $10.55-$10.75B; vanza triple and VX-548 NDAs by mid-2024

VERTEX PHARMACEUTICALS INC / MA

2023-FY EPS reported $13.89 revenue$9,869,200,000

FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).
FY24 product revenue guidance $10.55-$10.75B, reflecting CF growth and CASGEVY launch.
Completed pivotal studies for vanzacaftor triple (CF) and VX-548 (acute pain); NDAs to FDA by mid-2024.
CASGEVY approved in U.S., Great Britain, KSA, Bahrain; CHMP positive opinion; activated ATCs.
VX-880 Phase 1/2 study on protocol-specified pause; VX-264 advanced to Part B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VERTEX PHARMACEUTICALS INC / MA updated its the fourth quarter and full year ended December 31, 2023 guidance (raised).

Period: the fourth quarter and full year ended December 31, 2023
Guidance: raised
Result: reported results

Exact text from the filing

On February 5, 2024, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

2 earnings releases filed in the last 30 days. Browse all earnings releases →

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.